| Audience | Primary care and cannabis-medicine clinicians, psychiatrists, and patients considering CBD for stress or anxiety symptoms. |
| Primary Topic | A July 9, 2026 systematic review of 12 human neuroimaging studies testing whether CBD produces a consistent brain-based anxiolytic signature relative to placebo. |
| Source | Read the full source |
CBD for Anxiety: What 12 Brain-Imaging Studies Actually Show
A new PROSPERO-registered systematic review pooled every adult human neuroimaging study comparing CBD with placebo in stress and anxiety paradigms. Across 12 studies and 146 participants, brain-activity findings pointed in inconsistent directions, self-reported anxiety rarely improved more than placebo, and the certainty of evidence was rated Very Low. Here is what the review actually found, and what it does not settle.
| Study Type | Systematic review of adult human neuroimaging studies, PROSPERO registered |
| Registration | PROSPERO CRD420251063369 |
| Databases Searched | PubMed, Web of Science, EBSCO, ProQuest, through June 30, 2025 |
| Included Studies | 12 studies, 146 participants, 7 cohorts (published 2004 to 2025) |
| Screening | 1,470 records identified; 68 full texts assessed; 12 met eligibility |
| CBD Doses Used | Single doses from 125 mg to 800 mg across included studies |
| Risk of Bias Tool | Cochrane Risk of Bias 2 (RoB 2) |
| Certainty Framework | GRADE: neuroimaging Very Low, behavioral Very Low, physiological Low |
| Journal | Frontiers in Neuroimaging |
| Published | July 9, 2026 |
| DOI | 10.3389/fnimg.2026.1860919 |
| Authors | Rutledge O, Goyette RB, Wang KL, Park MS, Gabrieli JDE (MIT) |
| Clinical Use | Evidence-grading reference for patient counseling, not standalone treatment proof |
The review was not a single new brain-imaging trial of CBD. It was a preregistered synthesis of every eligible adult human study that scanned participants with fMRI, PET, or SPECT while comparing CBD against placebo in a stress or anxiety context, from the earliest eligible study in 2004 through mid-2025.
That design matters for how the findings should be read. The authors were not testing a single dose or paradigm. They were asking whether, across 12 independently designed studies, a consistent neural pattern for CBD emerged at all.
Across six task-based fMRI studies reporting whole-brain results, 44 peak coordinates were pooled into an anatomic vote count. The result was 12 votes for increased activation and 12 votes for decreased activation, with reported effects most frequently located in the occipital lobe, itself split between both directions.
A network-level analysis using the Yeo seven-network parcellation found a similar pattern: 8 votes for increased activation and 12 for decreased activation, with the ventral attention or salience network the only network showing a uniform direction, all three votes reflecting decreased activation. No single network was implicated consistently across all studies.
The amygdala is the brain region most often invoked in popular claims about CBD and anxiety, so the review’s amygdala-specific findings are worth isolating. One included study (Bird, 2022) found decreased left amygdala activation with CBD relative to placebo. A separate study using dynamic causal modeling (Fusar-Poli et al., 2010) found that CBD disrupted forward connectivity from the anterior cingulate cortex to the amygdala during a fearful-faces task.
These are real, individually reported findings, not fabricated ones, and they are consistent with a biologically plausible story. But they come from a small number of studies within a 12-study pool that, taken as a whole, did not converge on a single consistent regional or network-level pattern.
Brain-imaging changes and how anxious someone actually reports feeling are two different outcomes, and the review kept them separate. Across most of the included studies, no significant difference was found between CBD and placebo on subjective measures of anxiety or stress.
Two studies did report a modest reduction in self-reported anxiety with CBD relative to placebo, and one study (Zimmermann et al., 2025) found significantly reduced alcohol craving following cue exposure in participants who received CBD. These exceptions do not overturn the overall pattern, but they are part of the record and are reported here rather than omitted.
The GRADE framework rated certainty of evidence for neuroimaging measures and behavioral measures as Very Low, and for physiological measures as Low. Risk-of-bias assessments using RoB 2 generally showed either some concerns or high risk of bias across the included studies.
The authors also flagged that several reports drew on overlapping or partially overlapping participant cohorts, meaning the apparent number of independent findings overstates the actual independent evidence base. Combined with small sample sizes and study populations that were predominantly white and male, this substantially limits how far the findings can be generalized.
CED Clinic has previously covered a related brain-imaging finding in a different population: an acute oral THC study in adults with PTSD found that 5 mg and 10 mg doses reduced prefrontal activation during emotion regulation, yet produced no corresponding improvement in self-reported negative affect. That study and this CBD review point to the same underlying caution, that a measurable brain-imaging change does not automatically translate into a measurable symptom change.
CED has also covered a broader Lancet Psychiatry systematic review of RCT evidence for cannabinoids across psychiatric and neurological conditions, which identified significant gaps in standardized outcome measurement. This CBD neuroimaging review adds a specific, mechanism-level example of exactly that outcome-measurement gap.
I regularly hear patients describe CBD as something that will calm an overactive amygdala, usually repeating language from a product website rather than a study. This review is a useful corrective. Individual studies do report amygdala and amygdala-connectivity changes with CBD, so that language is not invented out of nothing, but the review makes clear those findings sit inside a small, heterogeneous, very-low-certainty evidence base rather than a settled neuroscience finding.
What I take from this into the exam room is not that CBD does nothing for stress or anxiety. Some patients report real subjective benefit, and a few of the included studies found modest reductions in self-reported anxiety. What I will stop doing is describing CBD’s mechanism in confident neuroanatomical terms it has not yet earned. The honest answer right now is that we do not have a consistent brain-imaging explanation for why some patients feel calmer on CBD.
How to Read a Neuroimaging Systematic Review Without Overclaiming or Dismissing It
Pooled neuroimaging reviews are easy to misread in either direction, either by citing one striking individual finding as if it were the field’s consensus, or by treating a Very Low certainty rating as proof that nothing is happening biologically.
The right approach is to separate what individual studies reported from what the pooled evidence, taken as a whole, actually supports.
Four questions worth asking before you trust a neuroimaging synthesis
How many independent cohorts actually contributed data?
This review’s 12 studies came from only seven independent cohorts, with some cohorts contributing more than one report. That is a smaller independent evidence base than the raw study count suggests.
Did the findings converge, or scatter?
The whole-brain, network-level, and SPECT perfusion analyses each showed activation changes in roughly equal numbers of increases and decreases, with no single brain region or network implicated consistently across studies.
Did brain changes track with how people actually felt?
Most included studies found no significant difference between CBD and placebo on self-reported anxiety, even when some individual brain-imaging changes were detected. Two studies were exceptions, reporting modest self-reported anxiety reductions.
What certainty grade did the authors themselves assign?
The GRADE framework rated neuroimaging and behavioral evidence Very Low and physiological evidence Low, which reflects both a small, heterogeneous evidence base and meaningful risk of bias across the RoB 2 assessments.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
What This Means If You Take (or Are Considering) CBD for Anxiety
If you were told CBD works by calming an overactive amygdala, this review shows that claim is based on a small number of individual studies rather than a consistent, replicated brain-imaging finding across the field.
That does not mean CBD is doing nothing for you if you feel calmer after taking it. Subjective response and neuroimaging convergence are different kinds of evidence, and this review specifically found that most studies did not show a self-reported anxiety benefit over placebo, though two did.
The most useful next step is discussing your specific goals, dose, and response pattern with your clinician rather than relying on mechanism claims from marketing material.
What a Responsible Clinician Can Say About This Finding
A responsible clinician can now say, with real evidentiary backing, that the human neuroimaging literature on CBD and anxiety is small, heterogeneous, and has not produced a consistent regional or network-level signature, despite individual studies reporting amygdala-related changes.
A responsible clinician should also avoid overstating the negative side of this finding. Two studies found modest self-reported anxiety improvement, and the review’s Very Low certainty rating reflects evidence quality and heterogeneity, not a conclusion that CBD is ineffective.
Why a Cautious Reader Should Slow Down
Only seven independent cohorts underlie the 12 included studies, and a planned quantitative meta-analysis could not be performed because too few studies reported comparable statistical detail. That is a narrow evidence base for a topic this widely discussed in consumer marketing.
A skeptical reader should also note that doses ranged from 125 mg to 800 mg across studies using different tasks and scanning modalities, which makes it difficult to know whether inconsistent findings reflect a truly inconsistent biological effect or simply methodological variation across small studies.
Where the Methodologic Pressure Points Are
The biggest pressure point is non-independence of findings. The authors explicitly note that overlapping peak coordinates across studies were often attributable to the same cohort, meaning the apparent volume of evidence overstates the number of truly independent replications.
A second pressure point is the demographic composition of the pooled sample. The authors state that participants were predominantly white males, which limits how confidently these findings, whatever direction they point, can be generalized to more diverse patient populations.
How This Fits With Earlier CED Coverage on Brain Imaging and Cannabinoids
CED Clinic previously covered an acute oral THC study in adults with PTSD that found reduced prefrontal activation during emotion regulation at 5 mg and 10 mg doses, without a corresponding improvement in self-reported negative affect. This CBD review reaches a structurally similar conclusion from a different angle: brain-imaging change and symptom change do not automatically move together.
CED has also covered a broader Lancet Psychiatry review documenting outcome-measurement gaps in cannabinoid psychiatric research generally. This review’s finding, that self-reported anxiety often did not track brain-imaging changes, is a concrete illustration of that broader measurement problem.
What Changes in the Exam Room
What changes is the specificity of the mechanism conversation. Clinicians can now cite a preregistered systematic review when explaining that CBD’s brain-imaging effects on stress and anxiety circuitry have not been consistently replicated across the available human studies.
What does not change is the value of tracking a given patient’s actual reported response. Since neuroimaging convergence was absent but a minority of studies did find self-reported anxiety benefit, individual response monitoring remains the most clinically useful signal available today.
What Better Evidence Needs Next
The authors call for standardized experimental paradigms, improved reporting practices, and more diverse, adequately powered samples to clarify the neural correlates of CBD’s effects on stress and anxiety.
Given that overlapping cohorts inflated the apparent evidence base in this review, independent replication in new, demographically diverse cohorts using consistent dosing and imaging protocols would meaningfully strengthen the next synthesis.
How This Review Could Be Distorted, and What It Actually Says
Distortion 1: “This proves CBD does nothing for anxiety.” False. Individual studies reported real brain-imaging changes, including amygdala-related findings, and two studies found modest self-reported anxiety benefit.
Distortion 2: “Brain scans confirm CBD calms the amygdala.” False. Only a small number of the 12 included studies reported amygdala-specific findings, and the pooled evidence across all regions and networks did not converge on a consistent pattern.
Distortion 3: “Very Low certainty means the study was poorly done.” False. The Very Low GRADE rating reflects the size, heterogeneity, and risk of bias in the underlying literature, not a flaw in this review’s own rigorous, preregistered methodology.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What did this new systematic review actually study?
It pooled every eligible adult human neuroimaging study, using fMRI, PET, or SPECT, that compared CBD with placebo in a stress or anxiety context, identifying 12 studies with 146 participants across seven cohorts published between 2004 and 2025.
Did the review find that CBD calms the amygdala?
A small number of the included studies reported amygdala-related findings, including decreased left amygdala activation in one study and disrupted amygdala-connectivity in another. But across all 12 studies and every brain region examined, no single consistent pattern emerged.
Did CBD reduce self-reported anxiety in these studies?
In most of the included studies, there was no significant difference between CBD and placebo on self-reported anxiety or stress. Two studies did find a modest reduction in self-reported anxiety with CBD, and one study found reduced alcohol craving after cue exposure.
What does a ‘Very Low certainty’ GRADE rating mean here?
It means the authors judged the neuroimaging and behavioral evidence to be of very low certainty due to small sample sizes, methodological heterogeneity, overlapping study cohorts, and risk of bias, not that CBD was proven ineffective.
How many studies and participants were included overall?
Twelve studies met eligibility criteria, comprising 146 participants across seven separate cohorts. Some cohorts contributed to more than one included study.
What CBD doses were used in the reviewed studies?
Single CBD doses across the included studies ranged from 125 mg to 800 mg. The review’s eligibility criteria accepted studies using doses from 100 mg to 1,000 mg.
Was this review preregistered?
Yes. It was registered in advance with PROSPERO under registration number CRD420251063369, and risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool.
Why couldn’t the authors run a full statistical meta-analysis?
A planned voxel-based meta-analysis using Seed-based d Mapping was attempted but could not be completed because too few studies reported comparable statistical information, so the authors used a narrative Synthesis Without Meta-analysis (SWiM) approach instead.
Does this mean patients should stop using CBD for anxiety?
Not necessarily, and that would be overreading the review. It addresses whether a consistent brain-imaging signature exists, not whether individual patients can experience subjective benefit. Any change in CBD use should be discussed with a treating clinician.
What should clinicians and patients take away from this review right now?
The most defensible takeaway is that current human neuroimaging evidence does not show a consistent, replicated brain-based mechanism for CBD’s anxiolytic effects, while individual studies and patient-reported responses remain areas worth tracking on a case-by-case basis with a treating clinician.
